

NIH142.001C1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gu, et al.) Group Art Unit 1645
Appl. No. : 09/610,034)
Filed : July 5, 2000)
For : LIPOOLIGOSACCHARIDE)
BASED VACCINES FOR)
PREVENTION OF)
MORAXELLA)
(BRANHAMELLA))
CATARRHALIS)
INFECTIONS IN HUMANS)
Examiner : K. Shahn-Shah)

#9
Plunkett
7/17/01
RECEIVED

JUL 10 2001

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In reply to the Restriction Requirement mailed March 29, 2001, Applicant responds as follows:

Restriction to one of the following groups was required under 35 USC 121:

Group I: Claims 1-10 and 35-38, drawn to a conjugate vaccine and pharmaceutical composition comprising the vaccine, classified in class 424, subclass 197.11.

Group II: Claims 11-13, drawn to lipooligosaccharide classified in class 536 subclass 123.1.

Appl. No. : 09/610,034
Filed : July 5, 2000

Group III: Claims 14-20, drawn to the method of preventing otitis media, classified in class 424, subclass 9.2.

Group IV: Claims 21-22, drawn to the method of detoxifying lipooligosaccharide, classified in class 435, subclass 72.

Group V: Claims 23-34, drawn to the method of making vaccine, classified in class 435, subclass 170.

In response to the restriction requirement, Applicant elects Group I, that is, Claims 1-10 and 35-38.

If any points remain that can be resolved by telephone, the Examiner is invited to contact the undersigned at the below-given telephone number.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6/27/01

By: 

Nancy W. Vensko
Registration No. 36,298
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(805) 547-5585

AMEND

O:\DOCS\CMS\CMS-1461.DOC
062501